IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v12y2014i5p537-546.html
   My bibliography  Save this article

The Impact on Health Outcomes and Healthcare Utilisation of Switching to Generic Medicines Consequent to Reference Pricing: The Case of Lamotrigine in New Zealand

Author

Listed:
  • Charon Lessing
  • Toni Ashton
  • Peter Davis

Abstract

Switching from brand to generic lamotrigine is largely devoid of adverse health outcomes; however, creating an incentive to ensure a greater proportion of patients switch to generic lamotrigine is required to achieve maximal financial savings from a policy of generic reference pricing. Copyright Springer International Publishing Switzerland 2014

Suggested Citation

  • Charon Lessing & Toni Ashton & Peter Davis, 2014. "The Impact on Health Outcomes and Healthcare Utilisation of Switching to Generic Medicines Consequent to Reference Pricing: The Case of Lamotrigine in New Zealand," Applied Health Economics and Health Policy, Springer, vol. 12(5), pages 537-546, October.
    • Handle: RePEc:spr:aphecp:v:12:y:2014:i:5:p:537-546
    DOI: 10.1007/s40258-014-0110-0
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40258-014-0110-0
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s40258-014-0110-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Schneeweiss, Sebastian, 2007. "Reference drug programs: Effectiveness and policy implications," Health Policy, Elsevier, vol. 81(1), pages 17-28, April.
    2. Dunne, Suzanne & Shannon, Bill & Hannigan, Ailish & Dunne, Colum & Cullen, Walter, 2014. "Physician and pharmacist perceptions of generic medicines: What they think and how they differ," Health Policy, Elsevier, vol. 116(2), pages 214-223.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Håkonsen, Helle & Horn, Anne Marie & Toverud, Else-Lydia, 2009. "Price control as a strategy for pharmaceutical cost containment--What has been achieved in Norway in the period 1994-2004?," Health Policy, Elsevier, vol. 90(2-3), pages 277-285, May.
    2. Mondelo-García, Cristina & Mendoza, Elvia & Movilla-Fernández, María-Jesús & Coronado, Carmen, 2018. "Perceptions of pharmacists and physicians on generic substitution in a financial crisis context in Northwestern Spain: A qualitative study," Health Policy, Elsevier, vol. 122(12), pages 1316-1325.
    3. Sabine Vogler & Guillaume Dedet & Hanne Bak Pedersen, 2019. "Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries," Applied Health Economics and Health Policy, Springer, vol. 17(6), pages 803-816, December.
    4. Boris Augurzky & Silja Göhlmann & Stefan Greß & Jürgen Wasem, 2009. "Effects of the German reference drug program on ex‐factory prices of prescription drugs: a panel data approach," Health Economics, John Wiley & Sons, Ltd., vol. 18(4), pages 421-436, April.
    5. Neil Hawkins & David A. Scott, 2011. "Reimbursement and value‐based pricing: stratified cost‐effectiveness analysis may not be the last word," Health Economics, John Wiley & Sons, Ltd., vol. 20(6), pages 688-698, June.
    6. Mousnad, Mohamed Awad & Shafie, Asrul Akmal & Ibrahim, Mohamed Izham, 2014. "Systematic review of factors affecting pharmaceutical expenditures," Health Policy, Elsevier, vol. 116(2), pages 137-146.
    7. Garattini, Livio & Cornago, Dante & De Compadri, Paola, 2007. "Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis," Health Policy, Elsevier, vol. 82(3), pages 330-339, August.
    8. Livio Garattini & Anna Padula, 2018. "Competition in pharmaceuticals: more product- than price-oriented?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 1-4, January.
    9. Greß, Stefan & Klaucke, Lena & Kötting, Cosima & May, Uwe & Wasem, Jürgen, 2008. "Preisregulierung von verschreibungspflichtigen Arzneimitteln in der gesetzlichen Krankenversicherung nach dem GKV-Wettbewerbsstärkungsgesetz," IBES Diskussionsbeiträge 170, University of Duisburg-Essen, Institute of Business and Economic Studie (IBES).
    10. Livio Garattini & Alessandro Curto & Nick Freemantle, 2016. "Pharmaceutical Price Schemes in Europe: Time for a ‘Continental’ One?," PharmacoEconomics, Springer, vol. 34(5), pages 423-426, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:12:y:2014:i:5:p:537-546. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.